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Abstract
The dopamine D2 and D3 receptors (D2R and D3R) are important targets for antipsychotics
and for the treatment of drug abuse. SB269652, a bitopic ligand that simultaneously binds
both the orthosteric binding site (OBS) and a secondary binding pocket (SBP) in both D2R
and D3R, was found to be a negative allosteric modulator. Previous studies identified
Glu2.65 in the SBP to be a key determinant of both the affinity of SB269652 and the magni-
tude of its cooperativity with orthosteric ligands, as the E2.65A mutation decreased both of
these parameters. However, the proposed hydrogen bond (H-bond) between Glu2.65 and
the indole moiety of SB269652 is not a strong interaction, and a structure activity relation-
ship study of SB269652 indicates that this H-bond may not be the only element that deter-
mines its allosteric properties. To understand the structural basis of the observed phenotype
of E2.65A, we carried out molecular dynamics simulations with a cumulative length of ~77 μs
of D2R and D3R wild-type and their E2.65A mutants bound to SB269652. In combination
with Markov state model analysis and by characterizing the equilibria of ligand binding
modes in different conditions, we found that in both D2R and D3R, whereas the tetrahydroi-
soquinoline moiety of SB269652 is stably bound in the OBS, the indole-2-carboxamide moi-
ety is dynamic and only intermittently forms H-bonds with Glu2.65. Our results also indicate
that the E2.65A mutation significantly affects the overall shape and size of the SBP, as well
as the conformation of the N terminus. Thus, our findings suggest that the key role of Glu2.65
in mediating the allosteric properties of SB269652 extends beyond a direct interaction with
SB269652, and provide structural insights for rational design of SB269652 derivatives that
may retain its allosteric properties.
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Author summary
G protein-coupled receptors (GPCRs) are targets of more than 25% of prescription drugs
on the market. Due to their critical roles in human physiology, competitive modulation of
these receptors has been found to be associated with many undesired side effects. Alloste-
ric modulation holds the promise of retaining normal receptor function and improving
selectivity. However, the underlying molecular mechanisms of the allosteric modulation
of GPCRs have remained largely uncharted. The dopamine D2-like receptors have been
implicated in voluntary movement, reward, sleep, learning, and memory. Based on previ-
ous experimental findings, we computationally characterized the binding of a negative
allosteric modulator of dopamine D2 and D3 receptors, and revealed the dynamic binding
mode of this modulator in a secondary binding pocket (SBP) of the receptors. Our results
highlight the key role of a Glu in mediating the allosteric properties of the modulator by
shaping the dynamically formed SBP, and shed light on rational design and optimization
of allosteric modulators of GPCRs.
Introduction
G protein-coupled receptors (GPCRs) represent one of the largest protein families, and regu-
late a myriad of physiological processes in response to diverse chemical or environmental sti-
muli [1]. Among this family, members of the dopamine D2-like receptor subgroup (consisting
of dopamine D2 receptor (D2R), D3R, and D4R) have been implicated in various physiological
functions, including voluntary movement, reward, sleep, learning, and memory [2]. Previous
studies have established dopamine D2-like receptors as important therapeutic targets for a
variety of neuropsychiatric disorders as well as for the treatment of drug addictions [2, 3].
Over the last two decades, significant efforts have been made towards understanding the struc-
ture-function relationships of these receptors [4–6]. Despite this success, the high sequence
identity within the subgroup presents a formidable challenge for selective drug development
[7].
In recent years, several bitopic ligands that target both the orthosteric binding site (OBS)
and a secondary “allosteric” binding site in GPCRs have been developed to achieve subtype
specificity, improve binding affinity, and lead to a reduction in the side effects compared to
orthosteric ligands [8]. Whereas most bitopic ligands show competitive behavior against other
ligands that bind the OBS [8], SB269652, a bitopic ligand for D2R and D3R, has been shown to
act as an allosteric modulator at both receptors [9–12]. SB269652 is composed of a tetrahydroi-
soquinoline (THIQ) and an indole-2-carboxamide moiety, connected by a cyclohexyl linker in
trans orientation. Molecular modeling of SB269652 in D2R showed that the THIQ moiety
binds in the OBS and forms an ionic interaction with Asp3.32 (superscripts denote Ballesteros-
Weinstein numbering [13]), while the indole-2-carboxamide moiety protrudes into a second-
ary binding pocket (SBP) formed by the extracellular portions of transmembrane segments
(TMs) 2 and 7. The pose in the SBP establishes a hydrogen bond (H-bond) between the N
atom of the indole-2-carboxamide and Glu2.65 [10]. An N-methyl indole-2-carboxamide deriv-
ative of SB269652 that is no longer able to make this interaction displayed competitive behav-
ior [14], consistent with an alteration in the binding of the ligand in the SBP. Derivatives based
on the indole-2-carboxamide moiety, N-isopropyl-1H-indole-2-carboxamide and N-butyl-1H-
indole-2-carboxamide, were recently found to display allosteric pharmacology in D2R and
D3R, respectively [12, 15], which suggest that the SBP near TMs 2 and 7 is indeed an allosteric
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binding site. In addition, SB269652 was inferred to mediate negative allosteric modulation
through a dimer interface of D2R [10]. Mutagenesis experiments implicated Glu2.65 near the
proposed TM1 dimer interface of D2R [16] as a key determinant for the activity of SB296652,
as replacement of this residue with alanine caused a decrease in both SB269652 affinity and
negative cooperativity [10]. Similar disruption by the E2.65A mutation of SB269652 binding
affinity was also observed at D3R.
However, as the proposed H-bond between Glu2.65 and the indole moiety of SB269652 is
not a strong interaction and the E2.65A mutation did not change the pharmacological profile of
SB269652 from allosteric to competitive, the H-bond may not be the only element to deter-
mine the allosteric properties [10, 14, 15]. Indeed, our structure activity relationship (SAR)
studies also suggested that the size and lipophilicity of the indole-2-carboxamide moiety were
also determinants of allosteric pharmacology [14]. Thus, another impact of the E2.65A muta-
tion, such as the potentially altered size and shape of the SBP in response to the mutation, may
also contribute to the decrease in affinity and negative cooperativity. In the present study, we
carried out extensive molecular dynamics (MD) simulations to characterize differences in the
binding modes of SB269652 in D2R or D3R, and the impact of the E2.65A mutation. Our
results elucidate important mechanistic details of the role of Glu2.65 in the SBP-mediated
change in binding affinity and negative cooperativity.
Results
Overview of MD simulations
We carried out comparative MD simulations of four conditions: D2R and D3R wild-type
(WT) and their E2.65A mutants bound to SB269652. The D2R models in complex with
SB269652 were derived from our previous study [10], whereas the starting poses of SB269652
in our D3R models are similar to those in D2R models (see Methods). The first set of simula-
tions was followed by multiple rounds of additional simulations, in which we collected more
trajectories for the under-sampled microstates based on the results of the Markov state model
(MSM) analysis [17, 18] (see Methods). In total, we collected 145 MD trajectories with a cumu-
lative length of 76.5 μs (Table 1).
The secondary pharmacophore of SB269652 is in a dynamic equilibrium in
the SBP of D2R and D3R WT
Similar to our previous study [10], in the resulting conformations from our extensive MD sim-
ulations, the primary pharmacophore (PP) of SB269652, the THIQ moiety, forms a salt bridge
with the carboxyl group of Asp3.32 in both D2R and D3R, a key component of ligand binding
to aminergic receptors [7]. The secondary pharmacophore (SP), which consists of an indole-
2-carboxamide moiety, attached to the PP through a trans-cyclohexylene linker, shows sig-
nificant dynamics in all our simulated conditions (Fig 1). To characterize the dynamics of the
SP poses, we performed MSM analysis to identify the thermodynamic populations of the
SB269652 binding poses and to calculate the kinetics of transitions between these populations.
Table 1. Summary of simulated conditions and simulation lengths.
Receptor Condition Number of trajectories Total length (μs)
D2R
WT 37 18.0
E2.65A 37 21.3
D3R
WT 36 21.3
E2.65A 35 15.9
Total 145 76.5
https://doi.org/10.1371/journal.pcbi.1005948.t001
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Fig 1. The SP of SB269652 is in dynamic equilibria of binding modes at D2R and D3R. Panels A and B show the
binding modes of SB269652 at D2R/WT and D3R/WT that H-bond with Glu2.65. Panels C and D are zoom-in views of
A and B respectively, with additional binding modes of the SP identified by MD simulations and MSM analysis. Our
MSM analysis identified two MSs of SP binding (shown in green and orange). The area of each of the spheres
representing a MS is proportional to its equilibrium probability (π); the transition rates between the MSs are shown
above the arrows connecting them. Panels E and F show the binding modes of SB269652 at mutant D2R/E2.65A and
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Specifically, we used 12 distances between the nitrogen atoms of SB269652 and the Cβ atoms
of selected binding-site residues and 4 intra-ligand measures as the input features (see Meth-
ods and S1 Fig). The analysis identified two metastable states (MSs) with similar equilibrium
probabilities of 52% and 48% in D2R/WT (shown as orange and green spheres in Fig 1C). In
the green MS, SB269652 forms two H-bonds to Glu2.65 with both the indole N4 and amide N3
atoms as we described previously [10] (Fig 2A and 2C). However, in the orange MS, the H-
bond between the N4 atom and Glu2.65 is lost as N4 reorients toward the extracellular side (Fig
1C). In addition, whereas N3 is in a similar orientation as in the green MS, it has significantly
reduced propensity to form a H-bond with Glu2.65 (Fig 2A and 2C).
In contrast to the observed dynamics of the SP among different MSs, in both green and orange
MSs, the PP is stable and the salt-bridge interaction between the charged N1 nitrogen in the PP
and the key binding-site residue Asp3.32 remained intact (S2A Fig), suggesting that the strong salt-
bridge interaction deters the dynamics of the SP from propagating to the PP, although we have
found that the poses of the PP and SP of bivalent ligands can affect each other [10, 20, 21].
For D3R/WT, we found that the two states identified by the MSM analysis are similar to
those in D2R/WT, in terms of the orientations of the indole-2-carboxamide moiety of
SB269652, relative to Glu2.65. Interestingly, in D3R/WT the orange MS in which the N4 atom
of SB269652 faces toward the extracellular side also has a slightly higher equilibrium probabil-
ity (53%) than the green MS (47%) with the N4 atom interacting with Glu2.65 (Fig 1D). Similar
to D2R/WT, the PP is stable in D3R/WT as well, with an intact interaction between the N1
nitrogen and Asp3.32 (S2B Fig).
The divergent poses of SB269652 in the OBS of D2R and D3R
Although the PP is stable in both D2R and D3R, we observed subtly different poses in the OBS
of these two receptors. Comparing the representative poses of SB269652 at D2R and D3R, we
noticed different interactions between the THIQ moiety and residues from extracellular loop 2
(EL2). Specifically, the subtle divergence of these two receptors at the interface between EL2
and EL1-TM2 accommodates the cyclohexyl linker of SB269652 slightly differently, and this
divergence appears to correlate with drastically different orientations of the conserved Ile at
the EL2.52 position (second residue after the conserved disulfide-bonded Cys in EL2): while
Ile183EL2.52 in D3R forms a favored hydrophobic interaction with the THIQ moiety in the
OBS, Ile184EL2.52 in D2R points upwards and is not in contact with SB269652 (Fig 3 and S1
Table). Such a difference is consistent with the results of our per-residue decompositions of
the MM/GBSA binding energy calculations of the representative D2/WT and D3/WT frames,
in which IleEL2.52 contributed favorably to binding of SB269652 at D3R but not at D2R.
In addition, we found that SB269652 interacts with Ser1935.42, Ser1945.43, and Ser1975.46 in
D2R, while it only interacts with Ser1925.42 in D3R. This is likely due to the divergence in both
EL2 and TM5 between D2R and D3R –in addition to the divergent EL2.51 and EL2.53 posi-
tions in EL2, TM5 is divergent at position 5.52 (Ile2035.52 in D2R and Gly2025.52 in D3R) near
the proline5.50-induced kink (Fig 3).
Previously, it was found that SB269652 had more than 10-fold higher binding affinity at
D3R than at D2R, and a chimera mutagenesis study that swapped the D2R and D3R segments
D3R/E2.65A constructs, from the same viewing angles as those in panels C and D. As demonstrated by the results of
MSM analysis, the mutation not only disrupts the equilibria of MSs observed in WT (Panel C and D), but also results
in distinct binding modes of the SP (brown and magenta MSs for D2R/E2.65A, and magenta MS for D3R/E2.65A). The
values from the maximum likelihood Bayesian Markov model and the upper and lower 1σ confidence intervals (in
superscript and subscript, respectively) for π and the transition rates from 500 Bayesian Markov model samples are
shown. Molecular graphics was generated using PyMOL (version 1.7.6.5, Schro¨dinger, LLC).
https://doi.org/10.1371/journal.pcbi.1005948.g001
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identified EL2 and TM5 to be important for the different binding affinities [9]. Thus, our find-
ings of the divergent poses of SB269652 in the OBS of D2R and D3R are highly consistent with
these results.
The E2.65A mutation alters the dynamics of the SP of SB269652 in the SBP
In comparison to D2R/WT, our MSM analysis identified 3 MSs for the D2R/E2.65A condition.
One MS of D2R/E2.65A is similar to the green MS of D2R/WT; however, given the absence of
Fig 2. Different binding modes of the SP occupy similar space in each receptor. Panels A (D2R/WT) and B (D3R/WT) show the protein residues within 5 Å of the
heavy atoms of SB269652 (interaction frequency>65%, S1 Table) for the green and orange MSs. Interacting residues shared between the two MSs are shown in grey;
residues forming unique interactions in one of the MSs are colored accordingly. The green MSs form direct H-bonds and the orange MSs form non-polar interactions
with Glu2.65 in both D2R/WT and D3R/WT, but the SP in green and orange MSs occupy similar spaces. Ligand interaction plots were generated using LigPlot+ [19]. The
shortest distance between the N3 atom of SB269652 and the carboxyl oxygen atoms of Glu2.65 is plotted against that between N4 and those oxygen atoms in each MS of
D2R/WT (Panel C) and D3R/WT (Panel D), showing the similar interaction patterns of the two MSs in the two receptors.
https://doi.org/10.1371/journal.pcbi.1005948.g002
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the H-bond between the indole-2-carboxamide moiety and Ala2.65, the indole ring of
SB269652 in the green MS of D2R/E2.65A tends to be more parallel to the membrane compared
to in D2R/WT (Fig 1E). In the dominant new pose of the SP in the D2R/E2.65A condition
(magenta MS in Fig 1E, which has an equilibrium probability of 60%), both the amide N3 and
indole N4 atoms face toward the extracellular side, but the amide O atom faces the intracellular
side, which is rarely observed in D2R/WT (Fig 1C and 1E). Interestingly in D3R/E2.65A, the
three MSs we identified (Fig 1F) have significant similarity to those three in the D2R/E2.65A, in
terms of the distances of N3 and N4 to Ala2.65 (S3 Fig). Even though the orange MS is the most
dominant MS (69%) in D3R/E2.65A instead of the magenta MS in D2R/E2.65A (Fig 1F), in both
mutant receptors, N4 of SB269652 has a similar tendency to face away from Ala2.65.
The E2.65A mutation affects the size and shape of the SBP in both D2R and
D3R
We hypothesized that in addition to the H-bonds between the indole-2-carboxamide moiety
of SB269652 and Glu2.65, another key to understanding the significance of the E2.65A mutation
on the allosteric action of SB269652 lies in conformational changes resulting from this muta-
tion. Our structural analysis identified marked conformational differences between the D2R/
WT and D2R/E2.65A conditions bound with SB269652, in the SBP consisting of TM1e, TM2e,
TM3e, and TM7e subsegments (see S2 Table for the division of subsegments [20, 22]). These
differences were characterized by a significantly larger TM2e-TM7e distance and a shorter
TM1e-TM3e distance in D2R/E2.65A as compared to the D2R/WT condition, demonstrating
the altered size and shape of the SBP in the mutant construct (Fig 4). Interestingly, the occupa-
tion of the SBP by the SP of SB269652 in D2R/WT increased both TM2e-TM7e and TM1e-
TM3e distances (Fig 4C) compared to the D2R/WT condition equilibrated with eticlopride
(Fig 4B and 4D), a ligand that predominantly occupies the OBS and does not protrude into the
Fig 3. Divergent interactions of SB269652 with EL2 and TM5 in D2R and D3R. IleEL2.51 in D2R forms direct hydrophobic
interactions with the cyclohexyl linker of SB269652 and Leu2.64 (A), while the aligned SerEL2.51 in D3R cannot (B), resulting in different
orientations of IleEL2.52 in these two receptors. In addition, the divergence in EL2 and near the proline-kink of TM5 (position 5.52)
contributes to the different interactions of the serines on top of TM5 with the cyano group of SB269652 (see text). Molecular graphics
was generated using PyMOL Molecular Graphics System (version 1.7.6.5, Schro¨dinger, LLC).
https://doi.org/10.1371/journal.pcbi.1005948.g003
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interface between TMs 2 and 7. Thus it appears that the SBP is dynamically formed to accom-
modate the SP of SB269652, and that the E2.65A mutation ablates the ability of SB269652 to
increase the distance of TM1e-TM3e through the interaction of its SP with the SBP.
A similar enlargement of the SBP by SB2696952 was observed for D3R/WT as well (Fig 4C
and 4D). Comparing the two D3R conditions bound with SB269652, the E2.65A mutation
results in larger TM2e-TM7e and smaller TM1e-TM3e distances, similar to the observations
for the D2R (Fig 4C).
Fig 4. Comparative conformational analysis shows significant changes induced by E2.65A in the SBP. The SBP is occupied in the presence of SB269652 (A) but not
eticlopride (ETQ, B), and is enclosed by the TM subsegments TM1e, TM2e, TM3e, and TM7e. The centers of mass for each of these TM subsegments are shown as black
spheres. Black dashed arrows indicate the distances measured in (C) and (D) for two TM subsegment pairs. The molecular graphics was generated using PyMOL (version
1.7.6.5, Schro¨dinger, LLC). (C) Distributions of distances between TM2e-TM7e are plotted against those of TM1e-TM3e distances for all the SB269652-bound conditions,
showing larger TM2e-TM7e distances and smaller TM1e-TM3e distances in the E2.65A conditions of both receptors. (D) The distributions of these distances for the ETQ-
bound conditions, when the SBP is not occupied. The MD simulation data of the ETQ-bound conditions were taken from [20].
https://doi.org/10.1371/journal.pcbi.1005948.g004
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In both D2R and D3R, Glu2.65 of TM2e faces Ser7.36 of TM7e, and we found that the disrup-
tion of this polar interface by the E2.65A mutation contributes to the larger TM2e-TM7e dis-
tances. However, Glu2.65 and Ser7.36 have a significant probability to form a H-bond in D3R/
WT (green MS, 54.7±0.6%; orange MS, 51.7±1.8%, for the dataset used in Fig 2) but not in
D2R/WT (green MS, 14.3±0.5%; orange MS, 9.0±1.3%). Thus, the TM2e-TM7e distance
appears to be larger in both the D2R/WT and D2R/E2.65A conditions than in D3R/WT and
D3R/E2.65A (Fig 4C), likely due to the shorter EL1 in D2R, consistent with our previous obser-
vations and with differences in the tendencies of this interface to accommodate the SP of the
bitopic ligands [23].
The impact of E2.65A on the SBP is associated with altered conformations of N terminus
(NT) as well. While the NT always adopts flexible loop conformations in our simulations, our
loop clustering analysis (see Methods) indicates clearly distinct equilibria and preferences of
the loop conformations in different conditions. For the combined analysis of D2R/WT and
D2R/E2.65A, we found that the mutation significantly shifts equilibrium of the NT conforma-
tion towards one of the two most populated clusters shown in WT, and has ~70% occupancy
for the dominant magenta MS of D2R/E2.65A (Fig 5 and S3 Table). Thus, the NT appears to be
Fig 5. The E2.65A mutation affects the conformational dynamics of the NT. For each indicated condition, an ensemble of five
representative frames of the largest NT cluster for each condition is shown. The N-terminal region is shown in black, and the
bound SB269652 is shown as grey sticks (with nitrogen and oxygen atoms colored in blue and red respectively), whereas the
residues at the 2.65 position are shown in cyan sticks. Molecular graphics was generated using PyMOL (version 1.7.6.5,
Schro¨dinger, LLC).
https://doi.org/10.1371/journal.pcbi.1005948.g005
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more dynamic in D2R/WT and adopts multiple conformations, whereas the E2.65A mutation
reduces such dynamics. Similarly, we found the most populated cluster in D3R/E2.65A has a
significant higher population and is significantly different from that of D3R/WT (Fig 5, S3
Table). Interestingly, it appears that residues 9–13 in D3R have a significant tendency to form
a helical conformation, whereas in D2R residues 20 and 21 are dominantly in a bend confor-
mation (S4 Fig). In all conditions, the NT bends down and forms a lid over the extracellular
vestibule bringing some of the residues in direct contact with the SP of the ligand (S1 Table).
Taken together, our data show that the E2.65A mutation alters the shape and size of the SBP
in both D2R and D3R, which in turn affects the NT conformation.
Discussion
In recent years, there have been significant advances in the development of allosteric modula-
tors for GPCRs that have high selectivity and novel modes of action. These modulators may
lead to therapeutic agents that have fewer side effects [24–26]. One such an example is
SB269652, which acts as a negative allosteric modulator in both D2R and D3R. Whereas our
previous studies identified Glu2.65 as a critical residue for allosteric modulation of SB269652
[10], our follow-up SAR study suggests that other elements are also involved in determining
the allosteric properties of SB269652 [14]. By carrying out comparative MD simulations in
combination with MSM analysis of D2R and D3R WT and their E2.65A mutants, we sought to
comprehensively characterize the binding poses and dynamics of SB269652 and the impact of
E2.65A mutation on the size and shape of the SBP.
The results of our MD simulations and MSM analysis revealed that in both D2R/WT and
D3R/WT, SB269652 has significant probabilities of not forming the H-bonds with Glu2.65, and
its SP is in dynamic equilibria between two poses, although they essentially occupy the same
space in the SBP in each receptor (Figs 1 and 2). These results suggest that the direct H-bond
interactions between the ligand SP and Glu2.65 are not the only factor that governs the alloste-
ric property of SB269652 in either D2R or D3R. Indeed, the mutation E952.65A did not cause a
switch from allosteric to competitive pharmacology, but rather caused a decrease in the affinity
and negative cooperativity of SB269652 [10]. The dynamic equilibria of the binding poses for
the allosteric moiety of SB269652 is likely a common feature shared by the binding of other
bitopic ligands in allosteric pockets–in many cases, such pockets of GPCRs are located at
peripheral regions, more exposed to the water milieu, and may have more dynamic and flexi-
ble properties than the OBS. While unlikely to be revealed by crystallography, such dynamic
features can be readily identified and characterized by extensive MD simulations in combina-
tion with MSM analysis.
Our results also indicate that the E2.65A mutation significantly alters the dynamic equilibria
of the SP of SB269652 in the SBP and results in new poses of the ligand. The new poses
(magenta MSs), although not observed in WT for both receptors, are similar to the orange
MSs of WT that have the N4 atom facing away from Glu2.65 (Figs 1C and 2A). From the per-
spective of receptor conformation, we found the substitution of the charged and larger Glu2.65
residue to a smaller Ala residue significantly affects the packing in the SBP, leading to larger
TM2e-TM7e and smaller TM1e-TM3e distances in both receptors (Fig 4). Thus, we propose
that the combined impact from both the removal of the H-bonds and the altered SBP is
responsible for the decrease in affinity and cooperativity of SB269652 observed in the E2.65A
mutants. Given the significant role of the size and shape of the SBP in mediating the allosteric
properties of SB269652, we can envision that some SB269652 derivatives may have allosteric
properties even without the capability of forming H-bonds with Glu2.65, as long as they can
induce the necessary conformational changes of the SBP. Such conformational changes may
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be impaired by the E2.65A mutation irrespective of whether a ligand has the capacity to H-
bond with Glu2.65. Of note, our SAR studies reveal that an N-methyl indole-2-carboxamide
derivative of SB269652 (MIPS1500) displayed apparently competitive behavior at D2R/WT,
but acted as a negative allosteric modulator of dopamine at D2R/E952.65A [10]. While such
observations may reflect the inability of this ligand to form a H-bond with Glu2.65 as we origi-
nally proposed, the addition of a methyl group also adds bulk to the SP. This may change its
orientation within the SBP. Thus, by changing the configuration of the SBP, the E952.65A
mutation may change the orientation of the N-methyl indole-2-carboxamide moiety of
MIPS1500 within the SBP causing the ‘gain’ of allosteric pharmacology. Indeed, the size of the
SP has also been shown to be an important determinant of the allosteric pharmacology of
SB269652, as derivatives in which the indole moiety was replaced by a pyrrole or proline moi-
ety display apparently competitive pharmacology at the D2R [14]. Such derivatives retain the
ability to form an interaction with Glu2.65 but lack the lipophilicity and bulk of the indole moi-
ety. Interestingly, our recent mutagenesis studies reveal that, in a similar manner to the N-
methyl indole moiety, the pyrrole derivative displays allosteric pharmacology at D2R/E952.65A
(Draper Joyce et al., manuscript in preparation). Such observations are consistent with the
conformation of the SBP, and the influence of the SP on this conformation, being central to
the allosteric pharmacology of SB269652.
Our results also show that the altered size and shape of the SBP in E2.65A mutants could
bias the NT towards specific conformations, and in the case of D3R, a distinct one from the
most populated conformation in the WT. In all conditions, the NT forms a lid over the extra-
cellular vestibule and is in direct interaction with SB269652, suggesting a previously unappre-
ciated role of the NT in ligand binding at D2R and D3R. Indeed, the functional roles of the NT
have been documented recently in a few closely related homologs, including the α1D-adrener-
gic [27], 5-HT2B [28] and μ-opioid receptors [29, 30]. By systematically examining all the avail-
able high-resolution crystal structures of class-A GPCRs bound to small compounds, we found
9 structures of 6 receptors showing direct interactions (within 5 Å of the heavy atoms) between
NT residues and the small-molecule ligands that at least partially occupy the OBS. Interest-
ingly, many of these small-molecule ligands protrude into the interface between TMs 2 and 7
(S5 Fig).
Taken together, our findings highlight the key role of the size and shape SBP, which is
determined by Glu2.65, in mediating the allosteric properties of SB269652, and provide struc-
tural insights for the rational design of SB269652 derivatives that may retain these allosteric
properties.
Methods
MD simulations
The binding mode of SB269652 at D2R was investigated based on our previous study [10].
Briefly, to acquire a reference binding mode of the PP (tetrahydroisoquinoline (THIQ)) of
SB269652 in the high-resolution crystal structure of D3R (PDB code 3PBL [31]), THIQ in the
protonated form was first docked into the D3R structure with the induced-fit docking (IFD)
protocol [32] implemented in Schro¨dinger suite (release 2016–1, Schro¨dinger, LLC: New
York, NY). The lowest MM/GBSA energy pose from the largest binding mode cluster was
selected as a reference pose for the PP of SB269652 at D3R. Assuming that binding modes of
THIQ in the near-identical OBSs of D3R and D2R should be similar, we docked the THIQ
into the D2R model [20, 21, 23, 31, 33] and selected a pose that is closest to the THIQ reference
pose in the D3R structure. The full-length SB269652 was then docked into the D2R and D3R
models by restraining the PP core [21] to the respective THIQ reference poses (with RMSD
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tolerance for the heavy-atom restraints of< 2.0 Å). To investigate the effect of the E2.65A
mutation, Glu2.65 was mutated to Ala in representative frames from equilibrated WT trajecto-
ries, and the charge of the system was neutralized by removing a Na+ ion from the water
milieu.
MD simulations of the receptor–ligand complexes were performed in the explicit water and
1-palmitoyl-2-oleoylphosphatidylcholine (POPC) lipid bilayer environment using Desmond
MD System (version 4.5; D. E. Shaw Research, New York, NY) with the CHARMM36 force
field [34–37] and TIP3P water model. The ligand parameters were obtained through the
GAAMP server [38], with the initial force field based on CGenFF assigned by ParamChem
[39]. The system charges were neutralized, and 150 mM NaCl was added. The average size of
the simulation systems was ~110000 atoms.
The protein-membrane relaxation was carried out with a protocol modified from that
developed by Schro¨dinger, LLC. Briefly, the initial energy minimization was followed by equil-
ibration with restraints on all protein and ligand heavy atoms in the beginning for 1 ns, then
with restraints only on the protein backbone and ligand heavy atoms for 6 ns. For both the
equilibrations and the following unrestrained production runs, we used Langevin constant
pressure and temperature dynamical system [40] to maintain the pressure at 1 atm and the
temperature at 310K, on an anisotropic flexible periodic cell with a constant-ratio constraint
applied on the lipid bilayer in the X-Y plane.
For each condition, we collected several rounds of multiple trajectories following the proce-
dure described below.
MSM analysis
The MSM analysis was performed using the PyEMMA program (version 2.3.2) [41]. For the
input featurizer, we chose the features based on the following considerations to describe the
interactions and orientations of SB269652 within the receptor binding sites. The polar and
charged interactions between the ligand and protein contribute significantly to ligand binding,
while these interactions can be more conveniently defined and characterized by simple geo-
metric measures, compared to hydrophobic and aromatic interactions. For SB269652, the
nitrogen atoms are distributed in both the THIQ and indole-2-caboxyamide moieties, so that
the dynamics of the entire ligand can be properly characterized using distances between these
atoms and protein residues. Therefore, we identified protein residues with their Cβ atoms
within 7.0 Å of any of the four nitrogen atoms of the SB269652, and used these Cβ-N distances
as input features. To better account for the orientation of the indole-2-caboxyamide moiety of
SB269652, two additional intramolecular distances from the N4 atom of indole ring were
included in the features—one to the N3 nitrogen and one to the oxygen of the amide bond.
Further, we calculated the vectors from the centers of mass of 5- or 6-member rings of the SP
to N4, and the projections of these vectors on the axis perpendicular to membrane were
included to identify the orientation of the indole ring relative to the plane of the membrane. In
total, 16 input features were used (S1 Fig).
The slow linear subspace of the input coordinates was estimated by the time-lagged inde-
pendent component analysis (TICA) [42, 43] on the combined data set of D2R/WT, D2R/
E2.65A, D3R/WT, and D3R/E2.65A conditions, and a dimension reduction was achieved by
projecting on the 4 slowest TICA components (which represent 61.7% of cumulative kinetic
variance). k-means clustering was then employed to discretize the simulated subspace and 100
microstates (MIs) were obtained. For a range of numbers of MIs (50, 75, 100, 150, 200, 300),
we estimated an MSM for each situation and concluded that the 100-MI MSM performs best
based on two analysis. We first calculated scores in terms of variational principle [44, 45],
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using cross-validation [46] as previously described [47]. This analysis showed the variational
scores were comparable for small numbers of MI and decreased when the number of MI is
larger than 150. In addition, the 100-MI MSM showed better convergence of the implied time
scales (ITS) in terms of the lag times (S6–S8 Figs).
The discretized combined data set was then divided into individual simulated conditions
to estimate Bayesian MSMs [48]. The Bayesian sampling was used to compute statistical
uncertainties of 500 transition matrix samples at each lag time. Convergence of ITS for all
MSMs was achieved at 96 ns lag time (S7 Fig), which was used to estimate Bayesian MSM for
each condition. The PCCA++ method [49] implemented in PyEMMA was then used to
stitch the MIs into metastable states (MSs). In the resulting MSMs, 2 MSs were assigned to
D2R/WT and D3R/WT conditions each, whereas 3 MSs were assigned to D2R/E2.65A and
D3R/E2.65A conditions each. The identity of common MSs between different conditions was
determined based on the number of shared MIs between them. Further structural and kinetic
analysis was performed using frames from those MIs that have > 70% probability belonging
to their respective MS.
In Fig 1, the transition rate between two MSs is the inverse mean first passage time, which
is the expected hitting time of one MS when starting from the other MS. The π value denotes
the equilibrium probability of a given MS, which is the probability to be in the MS that remains
unchanged in the Markov model as time progresses. The transition rate and equilibrium prob-
ability were computed as described previously [50].
The validity of the MSMs was assessed using Chapman-Kolmogorov tests (S9 and S10 Figs)
which showed that the MSMs estimated at 96 ns were consistent with the simulation data
within the 95% confidence interval computed by 500 bootstrapped samples of trajectories.
Generally, the Chapman–Kolmogorov test checks if the MSM models estimated at lag time τ
can be used to make predictions for the data at longer times kτ within statistical error, i.e., if
Eq (1) can be satisfied:
PðktÞ ¼ PkðtÞ ð1Þ
where P(τ) is the transition matrix estimated from the data at lag time τ (the Markov model),
and P(kτ) is the transition matrix estimated from the same data at longer lag times kτ. In prac-
tice, we use P(kτ) and Pk(τ), respectively, to propagate probability starting from one of the
metastable states, and measure how much probability ends up in each metastable state [47].
MSM-guided iterative MD sampling
To adequately and efficiently i) explore the conformational space and ii) sample the transitions
between MSs, we developed an iterative MD sampling protocol to guide the simulations to i)
the less-than-well-sampled regions and ii) the saddle points on the energy surface that are
likely in between MSs. Thus, by taking advantage of the MSM analysis after each round of sim-
ulations, we correspondingly identified both i) the single-frame microstates (MIs), and ii) the
under-sampled MIs (< 10 frames) that are in between MSs (i.e., the MIs having similar equi-
librium probabilities to be in two or more MSs), as the starting points for the next round of
simulations. For the selected MIs with more than one frames, we select the representative
frames from the more advanced stages of MD simulations. The procedure to identify the MIs
satisfying the criteria and to select the frame has been automated with an in-house python
script. For the MSM-guided simulations, we collected 300 ns for each trajectory. The simula-
tions were considered to have reached convergence until the biggest change in the equilibrium
probabilities for the updated MSMs of each condition was< 5% after including data from the
new round of the simulations.
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Conformational analysis
For the identifications of ligand contact residues shown in Fig 2, the results are based on 500
Bayesian Markov model samples 3 frames each from those MIs having > 70% probability of
belonging to each MS. For each of the MS we identified residues within 5.0 Å of ligand (heavy
atom-heavy atom distances) in D2R/WT and D3R/WT conditions, and the means and stan-
dard deviations of three sets of such samplings are shown in S1 Table.
For the sub-segment distance calculations shown in Fig 4, the TMs in both D2R and D3R
were divided into subsegments (extracellular, middle, and intracellular) as described in [20]
(see S2 Table), the results are based on 3000 Bayesian Markov model samples for each condi-
tion with the number of samples for each MS proportional to their equilibrium probability,
from those MIs having > 70% probability of belonging to each MS.
Clustering of the conformations of the N terminus
We performed the clustering analysis of the conformations of the N terminus (NT) using the
same dataset extracted for Fig 2 (see above) for each MS in each condition, and combined data
sets for one receptor together. The clustering is based on pairwise RMSD of selected NT resi-
dues by iteratively excluding the residues with high (> 5.0 Å) root mean squared fluctuation
(RMSF). The final clustering results are based on residues 6–20 and 22–30 for D2R and 2–25
for D3R to perform superimpositions and RMSD calculations. The computed RMSD matrix
was then subjected to hierarchical clustering using Ward algorithm implemented in SciPy.
The number of clusters for each receptor was determined so that the intra-cluster mean pair-
wise RMSD for each cluster is within 5.0 Å, unless the given cluster has less than 5% of the
total frames. The population of each cluster was re-weighted by equilibrium probabilities of
the MSs that their members belong to.
The means and standard deviations for the three largest clusters are shown in S3 Table.
Supporting information
S1 Fig. Chemical structure of SB269652 and the input features for MSM analysis. The tetra-
hydroisoquinoline (PP) and indole-2-carboxamide moiety (SP) of SB269652 are shown in
green and pink respectively. COM5 and COM6 refer to the centers of mass of the 5- and
6-member rings of the SP, respectively. The input features for MSM analysis include 12 dis-
tances from the nitrogen atoms of SB269652 to the indicated receptor Cβ atoms, 2 intramolec-
ular distances of SB269652, and the projections of the vectors from COM5 or COM6 to N4
along the axis perpendicular to membrane (see Methods).
(PDF)
S2 Fig. The salt bridge between the N1 atom of SB269652 and Asp3.32 remains stable in all
conditions. Distributions of the minimum distances between the N1 nitrogen atom of
SB269652 and carboxyl oxygen atoms of Asp3.32 for each MS of the indicated conditions are
shown. The MSs for each condition are colored according to Fig 1.
(PDF)
S3 Fig. Distribution of the distances from the N3 and N4 atoms of SB269652 to the Cβ
atom of Ala2.65 in mutant receptors. The MSs for each condition are colored according to Fig
1.
(PDF)
S4 Fig. Distribution of secondary structure content for each of the N terminal residues.
The secondary structures were classified by DSSP v2.0.4 [1]. The boundary between NT and
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TM1 is indicated by the dotted line.
(PDF)
S5 Fig. The high-resolution crystal structures of class-A GPCRs with the NT in contact
with small-molecule ligands. The NT is within 5 Å (heavy atom-heavy atom distance) of the
small-molecule ligands that at least partially occupy the OBS in the crystal structures of (A)
Chemokine receptors CCR2 (PDB: 5T1A) [1] and (B) CXCR4 (PDB: 3ODU) [2], (C) lysopho-
spholipid receptor-1 (PDB: 4Z34) [3], (D) μ-opioid receptor (PDB: 5C1M) [4], (E) sphingosine
1-phosphate receptor subtype 1(PDB: 3V2Y) [5], and (F) cannabinoid receptor CB1 (PDB:
5TGZ, 5U09, 5XR8, and 5XRA) [6–8].
(PDF)
S6 Fig. Implied time scales for 50- and 75-microstate MSMs. Implied timescales (ITS) are
plotted against lag time. The ITS of the maximum likelihood Bayesian Markov model are
shown in solid lines, whereas the means and the 95% confidence intervals (computed by
Bayesian sampling) are shown in dashed and shaded areas, respectively. In blue, red, and
green, . . . are the 1st, 2nd, and 3rd, . . . slowest ITS.
(PDF)
S7 Fig. ITS for 100- and 150-microstate MSMs. The color coding is the same as in S6 Fig.
(PDF)
S8 Fig. ITS for 200- and 300-microstate MSMs. The color coding is the same as in S6 Fig.
(PDF)
S9 Fig. Chapman-Kolmogorov test for D2R/WT and D2R/E2.65A. For each of the MSs in
our models we initialize the population in that state and compare the evolution of the popula-
tion predicted from the MSM at given lag times (dashed blue lines) to that measured on the
trajectories (black lines) at the same lag times. The shaded areas (light blue) represent 95%
confidence intervals computed by bootstrapping. The colors of the MSs are the same as in
Fig 1.
(PDF)
S10 Fig. Chapman-Kolmogorov test for D3R/WT and D3R/E2.65A. See S9 Fig for details.
(PDF)
S1 Table. SB269652 interacting residues. The means and standard deviations of the interac-
tion frequencies for each residue were calculated using 3 sets of 500 MSM Bayesian samples,
each set containing 1500 frames per MS. Residues having contact frequencies above 25% in at
least one of the MS are listed and the contact frequencies above 25% are in bold. OBS and SBP
residues are highlighted in cyan and yellow, respectively.
(PDF)
S2 Table. Definition of helical subsegments. Ballesteros-Weinstein numbering for the sub-
segments is given in parenthesis.
(PDF)
S3 Table. RMSD based clustering of the N terminus region. 3 sets of 500 Bayesian Markov
model samples were subjected to RMSD based clustering of the NT conformation. The per-
centage populations of the three largest clusters are shown, the populations of these clusters in
the most dominant MS in each condition are shown in bold. The numbers in parenthesis refer
to cluster ids.
(PDF)
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